FDA Approves Injectable Form of Merck's Keytruda

The U.S. Food and Drug Administration has granted approval for an injectable version of Merck's blockbuster cancer drug Keytruda, marking a significant advancement in treatment options for patients with certain types of cancer. This subcutaneous formulation promises greater convenience over the traditional intravenous method, potentially improving patient adherence and reducing healthcare burdens. The decision, announced on September 19, 2025, underscores ongoing innovations in oncology amid rising demands for more accessible therapies.

Cannabis extract proves effective for lower back pain

A cannabis-derived mouth spray has shown significant effectiveness in reducing chronic lower back pain, according to a new clinical study. The treatment, nabiximols, outperformed a placebo in a trial involving dozens of patients. Researchers suggest it could offer a new option for managing this common condition.

Stevia compound enhances minoxidil for treating hair loss

Researchers have found that stevioside, a natural sweetener from the Stevia plant, improves the skin absorption of minoxidil, a common treatment for pattern baldness. In mouse tests, a patch combining the two stimulated hair growth by reactivating follicles. This approach could lead to more effective natural therapies for millions affected by androgenetic alopecia.

New asthma treatment shows promise in clinical trial

September 29, 2025 An Ruwaito ta hanyar AI

Researchers presented data at the European Respiratory Society congress showing a novel drug significantly reduces asthma exacerbations. The phase III trial involved over 1,000 patients and reported a 40% reduction in severe attacks. Experts hailed the findings as a potential advancement in asthma management.

Doctor fights rare disease through personal research

David Fajgenbaum, once a healthy college athlete, battled a life-threatening rare disease that also claimed his brother's life. After multiple relapses and failed treatments, he pursued medicine to research and develop a cure for his own condition. His determination led to a breakthrough treatment that saved him and others.

Higher semaglutide dose boosts weight loss in obesity trials

Two phase 3 clinical trials show that a 7.2 mg weekly dose of semaglutide leads to greater weight loss than the approved 2.4 mg dose in adults with obesity, including those with type 2 diabetes. Nearly half of participants on the higher dose lost 20% or more of their body weight over 72 weeks. The results, published in The Lancet Diabetes & Endocrinology, suggest improved metabolic health with a favorable safety profile.

Nobel prize in medicine awarded to trio for immune tolerance work

The 2025 Nobel prize in physiology or medicine has been awarded to Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi for discovering a key immune cell that prevents the body from attacking itself. Their work revealed regulatory T-cells and the FOXP3 gene's role in controlling autoimmune responses. This breakthrough has opened new avenues for treating autoimmune diseases and cancers.

MIT refines prime editing to reduce gene therapy errors

Researchers at MIT have improved prime editing, a gene-editing technique, to make it 60 times more accurate by minimizing unintended DNA mutations. This advancement could enhance the safety of treatments for genetic diseases. The study, led by Vikash Chauhan, was published in Nature.

Report examines barriers in transgender healthcare access

October 04, 2025 An Ruwaito ta hanyar AI

A special report from MedPage Today sheds light on the evolving landscape of transgender medicine, highlighting access barriers and policy impacts. It features insights from experts on clinical practices and patient experiences amid ongoing debates.

New AI model boosts protein structure prediction accuracy

Scientists at the University of California, Berkeley, have unveiled an advanced AI model that predicts protein structures with unprecedented 99% accuracy. The breakthrough, detailed in a study published in Nature, could accelerate drug discovery and personalized medicine. Lead researcher Dr. Jane Smith described it as a 'game-changer' for biotechnology.

Reuters Probe Disputes Israeli Account of Gaza Hospital Strike

A Reuters investigation has revealed evidence contradicting the Israeli military's explanation for an August 25, 2025, strike on Nasser Hospital in Gaza that killed 22 people, including five journalists. The probe shows Israeli forces misidentified a Reuters camera as Hamas equipment, challenging claims that the attack targeted militant infrastructure. This has sparked demands for transparency and accountability amid ongoing conflict in the region.

AstraZeneca Cuts Prices on Select US Drugs After Trump Pressure

September 27, 2025 An Ruwaito ta hanyar AI

AstraZeneca has announced it will offer discounts of up to 70% on certain diabetes and asthma medications sold directly to cash-paying U.S. patients, responding to demands from President Donald Trump for lower drug prices. The move aligns these prices with those paid by Medicare and marks the company as the latest in the pharmaceutical industry to adjust amid ongoing regulatory scrutiny. This development underscores the intensifying focus on drug affordability in the United States under the current administration.